Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05207644 · ClinicalTrials.gov registry record · Phase 2

Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation

A Phase 2 study, sponsored by Gynuity Health Projects.

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT05207644 is a Phase 2 study that has completed, run by Gynuity Health Projects. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05207644, a Phase 2 study, has completed, sponsored by Gynuity Health Projects.

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

Study to determine if a user-friendly medical abortion regimen using letrozole and misoprostol is safe and acceptable.

Interventions

  • DRUG 30 mg letrozole followed by 800 mcg misoprostol

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-12-09
Est. Completion 2022-04-30
Phase Phase 2

Sponsor

Gynuity Health Projects

29 total trials

What the Registry Record Tells You About NCT05207644

The ClinicalTrials.gov registry entry for NCT05207644 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynuity Health Projects, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which 30 mg letrozole followed by 800 mcg misoprostol is the first listed.

NCT05207644 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05207644 about?

NCT05207644 is a clinical study titled "Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation". Study to determine if a user-friendly medical abortion regimen using letrozole and misoprostol is safe and acceptable.

What is the current status of trial NCT05207644?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-12-09. Estimated completion is 2022-04-30.

What interventions are being tested in trial NCT05207644?

The interventions under investigation include: 30 mg letrozole followed by 800 mcg misoprostol (DRUG).

Who is sponsoring clinical trial NCT05207644?

This trial is sponsored by Gynuity Health Projects, which has 29 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.